ArticleTranslational andrology and urology2026
Comorbidity alterations between time for diagnosis and radical cystectomy in patients with muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comorbidity alterations during neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC) are not well studied. Comorbidity-estimates are mainly based on calculations at diagnosis. It is unknown if comorbidities alter in this patient group. This study aimed to investigate if comorbidity alterations during treatment need to be considered, for scientific evaluations. Methods: A retrospective study of comorbidity alterations on MIBC patients undergoing NAC using age adjusted Charlson Comorbidity Index (CACI). We identified 684 patients between 2007-2022 from four Swedish cystectomy centers, a total of 320 were enrolled in the study. Inclusion criteria were nondisseminated MIBC, cT2-4aN0M0, NAC-treatment or NAC-eligibility. Medical files were reviewed and CACI were assessed and graded at three checkpoints during treatment: At diagnosis, post-NAC and pre-surgery. The cohort was divided into three subgroups, NAC complete, NAC incomplete and NAC-eligible. Data was retrospectively analyzed in SPSS Statistics 29.0 using descriptive statistics, one-way analysis of variance (ANOVA) and t-test. Results: The total cohort (n=320) had an increase in CACI, 0.11 CACI points, between diagnosis and prior to surgery [95% confidence interval (CI): 0.06-0.15, P<0.001]. The NAC-incomplete group had the highest increase in CACI, 0.21 CACI points from diagnosis to pre-surgery (95% CI: 0.03-0.39, P=0.01). The NAC-complete group also had an increase in CACI, 0.11 CACI points from diagnosis to pre-surgery (95% CI: 0.06-0.15, P<0.001). The NAC-eligible group had no significant CACI-alterations. The most common events causing an increase in CACI was suspected peptic ulcer (85.2%). Conclusions: There is a statistically significant increase of comorbidity in the total cohort as well as for two of the three subgroups, the NAC complete group and the NAC incomplete group. However, the increases are subtle and of limited clinical significance. This suggests that regardless of adverse events, complications, or progression, comorbidities only slightly change over time in the patient group. All together, answering the primary question if a comorbidity measurement at any moment on the timeline is sufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.